Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan

被引：0
|
作者：
Hsia, T. [1 ]
Chang, G. [2 ]
Chen, Y. [3 ]
Lin, M. [4 ]
Su, W. [5 ]
Tsai, C. [3 ,6 ]
Tsai, C. [3 ,6 ]
Yang, L. [6 ]
机构：
[1] China Med Univ Hosp, Dept Pulm Med, Taichung, Taiwan
[2] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan
[3] Vet Gen Hosp, Chest Dept, Taipei, Taiwan
[4] Chang Guang Mem Hosp, Dept Pulm & Crit Care Med, Kaohsiung, Taiwan
[5] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[6] Roche Prod Ltd, Dept Pharma, Taipei, Taiwan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71386-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6558
引用
收藏
页码：375 / 375
页数：1
相关论文
共 50 条
  • [21] Erlotinib A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer
    Lyseng-Williamson, Katherine A.
    PHARMACOECONOMICS, 2010, 28 (01) : 75 - 92
  • [22] Second-line erlotinib for non-small-cell lung cancer Reply
    Ciuleanu, Tudor
    LANCET ONCOLOGY, 2012, 13 (04): : E142 - E142
  • [23] Single agents in the second-line treatment of non-small cell lung cancer
    Belani, CP
    SEMINARS IN ONCOLOGY, 1998, 25 (03) : 10 - 14
  • [24] An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer
    Scagliotti, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2855 - 2866
  • [25] Geographic variation in the second-line treatment of non-small cell lung cancer
    Edelman, MJ
    Sekine, I
    Tamura, T
    Saijo, N
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S39 - S44
  • [26] The safety of second-line treatment options for non-small cell lung cancer
    Rossi, Antonio
    Maione, Paolo
    Santabarbara, Giuseppe
    Sacco, Paola Claudia
    Casaluce, Francesca
    Sgambato, Assunta
    Barzelloni, Maria Luisa
    Palazzolo, Giovanni
    Gridelli, Cesare
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 471 - 479
  • [27] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [28] Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
    Caceres-Lavernia, Haslen H.
    Neninger-Vinageras, Elia
    Varona-Rodriguez, Leslie M.
    Olivares-Romero, Yoli A.
    Sanchez-Rojas, Irlis
    Mazorra-Herrera, Zaima
    Basanta-Bergolla, Denenke
    Duvergel-Calderin, Dayanis
    Torres-Cuevas, Boris L.
    del Castillo-Carrillo, Concepcion
    MEDICC REVIEW, 2021, 23 (3-4) : 21 - 28
  • [29] Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer
    Gebbia, Vittorio
    Bellavia, Massimo
    Banna, Giuseppe Luigi
    Russo, Paolo
    Ferrau, Francesco
    Tralongo, Paolo
    Borsellino, Nicolo
    CLINICAL LUNG CANCER, 2013, 14 (04) : 390 - 398
  • [30] Future directions in the second-line treatment of non-small cell lung cancer
    Rosell, R
    Cecere, F
    Cognetti, F
    Cuello, M
    Sanchez, JM
    Taron, M
    Reguart, N
    Jablons, D
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S45 - S51
12345